DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Net Loss Per Share (Tables)

Note 11 - Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Net loss		$	(3,059	)		$	(3,450	)		$	(9,925	)		$	(10,346	)
Weighted average shares outstanding—basic and diluted			26,443,067				19,035,713				26,443,067				18,863,829
Basic and diluted net loss per share		$	(0.12	)		$	(0.18	)		$	(0.38	)		$	(0.55	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		Three Months Ended September 30,								Nine Months Ended September 30,
		2022				2021				2022				2021
Employee and non-employee stock options			2,775,998				1,959,100				2,775,998				1,959,100
Common shares issuable under common share purchase warrants			265,000				265,000				265,000				265,000
Common shares issuable under deferred stock units			134,402				71,509				134,402				71,509